Pharma Penny Stock Under Rs 60: Largest Manufacturers of Microcrystalline Cellulose Gets Environmental Nod for New API Facility in Andhra Pradesh
The company has delivered a three-year return of 120.12 per cent but recorded a one-year return of -12.09 per cent.
Today, shares of Sigachi Industries Ltd gained 061 per cent to Rs 57.80 per share from its previous closing of Rs 57.45 per share.
Sigachi Industries Limited, a Small-Cap pharmaceutical company, has taken a significant step forward in its expansion journey. The company recently received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for its new manufacturing unit. The upcoming facility, to be located in Orvakal, Kurnool District, spans 25.09 acres and is expected to bolster Sigachi’s manufacturing capabilities in bulk drugs, drug intermediates, and specialty chemicals.
DSIJ offers a service 'Pop Stock" with recommendations for intraday trading based on research and analysis to help subscribers make healthy profits. If this interests you, download the service details pdf here
The strategic investment is aligned with the “Make in India” initiative, aimed at increasing domestic production capacity and reducing import dependency in the pharmaceutical sector. The facility is designed to cater to both regulated and semi-regulated global markets, potentially enhancing Sigachi’s export footprint across over 60 countries, including the Middle East, Europe, and the Americas.
Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated - “This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets. At Sigachi, we are strategically positioning ourselves to cater to increasing global demand Friday, 13th June 2025: Sigachi Industries Limited, a leading player in pharmaceutical excipients and active ingredients, has received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh for its upcoming Bulk Drugs, Drug Intermediates, and Specialty Chemicals facility at Orvakal, Kurnool District. by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements.”
The stock has a 52-week high of Rs 66.97 and a 52-week low of Rs 34.95. The company has delivered a three-year return of 120.12 per cent but recorded a one-year return of -12.09 per cent. Its current Price-Earnings (PE) Ratio stands at 30.17, and the market capitalisation is Rs 2,195 crore.
Sigachi operates primarily in three segments—Microcrystalline Cellulose (MCC), which contributes 75 per cent to its revenue, Operations & Management (O&M), and Active Pharmaceutical Ingredients (API). Between FY20 and FY24, Sigachi reported a revenue growth of 138 per cent, with its O&M division growing by 219 per cent. The company has expanded its API segment through the acquisition of Trimax Bio Sciences Private Ltd. Additionally, it has invested in R&D through two dedicated centers and several registered patents, further strengthening its focus on quality and innovation.
Prominent public shareholders in Sigachi Industries include Rakesh Yadav (2.80 per cent), Llp (1.90 per cent), Sudhir Yadav (1.86 per cent), and Maheshwari Vijaybhai Bhavsar (1.39 per cent).
The company announced positive Quarterly Results (Q4FY25) and annual results (FY25). According to quarterly results, revenue increased by 23 per cent to Rs 128.21 crore, EBITDA increased by 30 per cent to Rs 30.75 crore and net profit increased by 7 per cent to Rs 16.17 crore in Q4FY25 compared to Q4FY24. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24. The Board recommended a final dividend of Re 0.10 per share, subject to approval of members at the ensuing Annual General Meeting.
Sigachi Industries Limited acquired 1,07,17,672 equity shares in Trimax Bio Sciences Private Limited for Rs 37.22 crore, converting an existing advance/loan into equity, subject to shareholder approval. This comes as Sigachi's subsidiary, Trimax Bio Sciences Pvt Ltd, recently received a Certificate of Suitability (CEP) for Metformin Hydrochloride from the EDQM, a significant milestone that allows Trimax to export this crucial API to Europe and other recognised markets. This certification not only strengthens Sigachi's position in regulated pharmaceutical landscapes but also aligns with its strategic goal of expanding into regions with high demand for essential pharmaceutical ingredients like Metformin, which is widely used for type 2 diabetes.
Disclaimer: The article is for informational purposes only and not investment advice.